JP2025525305A5 - - Google Patents
Info
- Publication number
- JP2025525305A5 JP2025525305A5 JP2024570660A JP2024570660A JP2025525305A5 JP 2025525305 A5 JP2025525305 A5 JP 2025525305A5 JP 2024570660 A JP2024570660 A JP 2024570660A JP 2024570660 A JP2024570660 A JP 2024570660A JP 2025525305 A5 JP2025525305 A5 JP 2025525305A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- fusion protein
- protein
- domain
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22182401 | 2022-06-30 | ||
| EP22182401.4 | 2022-06-30 | ||
| EP22205669 | 2022-11-04 | ||
| EP22205669.9 | 2022-11-04 | ||
| PCT/EP2023/068109 WO2024003393A1 (en) | 2022-06-30 | 2023-06-30 | Fusion proteins with half life extending domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025525305A JP2025525305A (ja) | 2025-08-05 |
| JP2025525305A5 true JP2025525305A5 (https=) | 2026-03-03 |
Family
ID=87136437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024570660A Pending JP2025525305A (ja) | 2022-06-30 | 2023-06-30 | 半減期延長ドメインを有する融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250388696A1 (https=) |
| EP (1) | EP4547708A1 (https=) |
| JP (1) | JP2025525305A (https=) |
| CN (1) | CN119487061A (https=) |
| AU (1) | AU2023301542A1 (https=) |
| CA (1) | CA3253055A1 (https=) |
| WO (1) | WO2024003393A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025125378A1 (en) * | 2023-12-12 | 2025-06-19 | Navigo Proteins Gmbh | Novel serum albumin-binding fusion proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1208155A1 (en) * | 2012-03-28 | 2016-02-26 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
| US11414466B2 (en) * | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
| JP7611173B2 (ja) * | 2019-06-04 | 2025-01-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｆａｐ結合タンパク質及びそれらの使用 |
| EP4161954B1 (en) * | 2020-07-16 | 2023-11-01 | Navigo Proteins Gmbh | Serum stable binding proteins for human her2 for theranostic applications |
-
2023
- 2023-06-30 US US18/880,225 patent/US20250388696A1/en active Pending
- 2023-06-30 CA CA3253055A patent/CA3253055A1/en active Pending
- 2023-06-30 JP JP2024570660A patent/JP2025525305A/ja active Pending
- 2023-06-30 AU AU2023301542A patent/AU2023301542A1/en active Pending
- 2023-06-30 EP EP23737978.9A patent/EP4547708A1/en active Pending
- 2023-06-30 WO PCT/EP2023/068109 patent/WO2024003393A1/en not_active Ceased
- 2023-06-30 CN CN202380050753.0A patent/CN119487061A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP7536424B2 (ja) | 多重特異性分子 | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2020506898A5 (https=) | ||
| Müller et al. | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain | |
| JP2021526816A5 (https=) | ||
| JP2021505155A (ja) | 多重特異性分子及びその使用 | |
| JP2022524338A5 (https=) | ||
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JPH02500329A (ja) | ターゲット化多機能蛋白質 | |
| JP2020522267A (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2024507540A5 (https=) | ||
| JP2016520053A5 (https=) | ||
| JP2020519696A (ja) | 多重特異性タンパク質薬物およびそのライブラリー、ならびに製造方法と使用 | |
| KR20230141817A (ko) | 이중특이 항체 | |
| JP2024507693A5 (https=) | ||
| JP2015520172A5 (https=) | ||
| CN115028719B (zh) | 血清白蛋白结合纳米抗体及其制备方法与应用 | |
| JP2005522192A5 (https=) | ||
| JP2025525305A5 (https=) | ||
| AU2014241891B2 (en) | Ribotoxin molecules derived from sarcin and other related fungal ribotoxins | |
| IL305186A (en) | Compounds and methods for extending half life of biomolecules | |
| CN117820475B (zh) | 针对il-17a的新型纳米抗体、药物、制备、方法及应用 | |
| Tillib et al. | Extending linker sequences between antigen-recognition modules provides more effective production of bispecific nanoantibodies in the periplasma of E. coli |